51/120
2.1 / 5 stars
All 120 Win/Lose results shown below
ANIP Roast Me summary
ANI PHARMACEUTICALS INC (ANIP). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 24 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseANIP / S&P 7.65% / 15.20% |
WinANIP / S&P 30.90% / 15.00% |
LoseANIP / S&P ANIP unavailable / 50.40% |
| 2026-Q12/3 |
WinANIP / S&P -2.58% / -4.33% |
WinANIP / S&P 37.03% / 11.30% |
LoseANIP / S&P ANIP unavailable / 27.70% |
| 2025-Q41/3 |
LoseANIP / S&P -13.82% / 2.65% |
WinANIP / S&P 43.78% / 9.00% |
LoseANIP / S&P ANIP unavailable / 13.40% |
| 2025-Q32/3 |
WinANIP / S&P 40.38% / 8.12% |
WinANIP / S&P 48.87% / 4.61% |
LoseANIP / S&P ANIP unavailable / 13.45% |
| 2025-Q21/3 |
LoseANIP / S&P -2.54% / 10.94% |
WinANIP / S&P 38.68% / 4.83% |
LoseANIP / S&P -166.96% / 10.63% |
| 2025-Q12/3 |
WinANIP / S&P 21.11% / -4.27% |
WinANIP / S&P 30.26% / 4.98% |
LoseANIP / S&P -180.38% / 10.57% |
| 2024-Q41/3 |
LoseANIP / S&P -7.34% / 2.41% |
WinANIP / S&P 26.20% / 5.25% |
LoseANIP / S&P -222.35% / 6.15% |
| 2024-Q31/3 |
LoseANIP / S&P -6.31% / 5.89% |
WinANIP / S&P 23.60% / 5.89% |
LoseANIP / S&P -211.76% / 6.11% |
| 2024-Q21/3 |
LoseANIP / S&P -7.88% / 4.28% |
WinANIP / S&P 34.27% / 5.38% |
LoseANIP / S&P ANIP unavailable / 5.12% |
| 2024-Q12/3 |
WinANIP / S&P 25.37% / 10.56% |
WinANIP / S&P 44.26% / 5.71% |
LoseANIP / S&P ANIP unavailable / 5.59% |
| 2023-Q41/3 |
LoseANIP / S&P -5.03% / 11.69% |
WinANIP / S&P 53.87% / 6.81% |
LoseANIP / S&P ANIP unavailable / 7.78% |
| 2023-Q32/3 |
WinANIP / S&P 7.86% / -3.27% |
WinANIP / S&P 58.75% / 7.52% |
LoseANIP / S&P ANIP unavailable / -5.03% |
| 2023-Q22/3 |
WinANIP / S&P 35.52% / 8.74% |
WinANIP / S&P 59.71% / 9.50% |
LoseANIP / S&P ANIP unavailable / -8.57% |
| 2023-Q11/3 |
LoseANIP / S&P -1.27% / 7.50% |
WinANIP / S&P 58.65% / 10.77% |
LoseANIP / S&P ANIP unavailable / -15.69% |
| 2022-Q42/3 |
WinANIP / S&P 25.17% / 7.56% |
WinANIP / S&P 46.38% / 11.88% |
LoseANIP / S&P ANIP unavailable / -17.99% |
| 2022-Q32/3 |
WinANIP / S&P 8.32% / -4.88% |
WinANIP / S&P 33.24% / 13.47% |
LoseANIP / S&P ANIP unavailable / -1.41% |
| 2022-Q22/3 |
WinANIP / S&P 5.55% / -16.10% |
WinANIP / S&P 17.78% / 13.71% |
LoseANIP / S&P ANIP unavailable / 11.04% |
| 2022-Q10/3 |
LoseANIP / S&P -39.00% / -4.60% |
LoseANIP / S&P 6.04% / 15.97% |
LoseANIP / S&P ANIP unavailable / 42.23% |
| 2021-Q41/3 |
WinANIP / S&P 40.40% / 11.03% |
LoseANIP / S&P 3.67% / 15.00% |
LoseANIP / S&P ANIP unavailable / 96.40% |
| 2021-Q30/3 |
LoseANIP / S&P -6.36% / 0.58% |
LoseANIP / S&P 6.66% / 10.77% |
LoseANIP / S&P ANIP unavailable / 69.42% |
| 2021-Q21/3 |
LoseANIP / S&P -3.02% / 8.55% |
WinANIP / S&P 8.01% / 6.58% |
LoseANIP / S&P ANIP unavailable / 51.81% |
| 2021-Q12/3 |
WinANIP / S&P 24.45% / 6.17% |
WinANIP / S&P 4.81% / -1.06% |
LoseANIP / S&P ANIP unavailable / 7.39% |
| 2020-Q41/3 |
LoseANIP / S&P 2.94% / 12.15% |
WinANIP / S&P 0.93% / -3.72% |
LoseANIP / S&P -476.00% / -33.42% |
| 2020-Q30/3 |
LoseANIP / S&P -12.77% / 8.93% |
LoseANIP / S&P -7.66% / -2.04% |
LoseANIP / S&P -247.01% / -27.10% |
| 2020-Q20/3 |
LoseANIP / S&P -20.62% / 20.54% |
LoseANIP / S&P -8.15% / -0.46% |
LoseANIP / S&P -217.36% / -27.11% |
| 2020-Q10/3 |
LoseANIP / S&P -33.94% / -19.60% |
LoseANIP / S&P -2.19% / 3.47% |
LoseANIP / S&P -111.40% / -14.75% |
| 2019-Q40/3 |
LoseANIP / S&P -15.38% / 9.07% |
LoseANIP / S&P 2.47% / 5.36% |
LoseANIP / S&P -61.54% / 2.99% |
| 2019-Q32/3 |
LoseANIP / S&P -11.34% / 1.70% |
WinANIP / S&P 12.50% / 5.02% |
WinANIP / S&P 6600.00% / 0.21% |
| 2019-Q22/3 |
WinANIP / S&P 16.53% / 4.30% |
WinANIP / S&P 13.67% / 6.64% |
LoseANIP / S&P ANIP unavailable / 8.65% |
| 2019-Q12/3 |
WinANIP / S&P 56.69% / 13.65% |
WinANIP / S&P 11.40% / 8.12% |
LoseANIP / S&P ANIP unavailable / 14.29% |
| 2018-Q41/3 |
LoseANIP / S&P -20.37% / -13.52% |
WinANIP / S&P 13.99% / 9.05% |
LoseANIP / S&P ANIP unavailable / 18.23% |
| 2018-Q31/3 |
LoseANIP / S&P -15.36% / 7.71% |
WinANIP / S&P 14.29% / 10.21% |
LoseANIP / S&P -96.88% / 19.06% |
| 2018-Q22/3 |
WinANIP / S&P 14.74% / 3.43% |
WinANIP / S&P 19.66% / 9.03% |
LoseANIP / S&P -100.00% / 14.46% |
| 2018-Q11/3 |
LoseANIP / S&P -9.67% / -0.76% |
WinANIP / S&P 29.03% / 7.68% |
LoseANIP / S&P -100.00% / 12.46% |
| 2017-Q42/3 |
WinANIP / S&P 22.79% / 6.64% |
WinANIP / S&P 37.49% / 7.03% |
LoseANIP / S&P -126.47% / 13.82% |
| 2017-Q32/3 |
WinANIP / S&P 12.16% / 4.48% |
WinANIP / S&P 54.69% / 5.68% |
LoseANIP / S&P -7.25% / 17.57% |
| 2017-Q21/3 |
LoseANIP / S&P -5.47% / 3.09% |
WinANIP / S&P 75.89% / 4.83% |
LoseANIP / S&P -46.51% / 17.74% |
| 2017-Q11/3 |
LoseANIP / S&P -18.33% / 6.07% |
WinANIP / S&P 85.32% / 3.67% |
LoseANIP / S&P -69.16% / 13.32% |
| 2016-Q41/3 |
LoseANIP / S&P -8.64% / 3.82% |
WinANIP / S&P 68.53% / 2.09% |
LoseANIP / S&P -74.24% / 7.05% |
| 2016-Q32/3 |
WinANIP / S&P 18.86% / 3.85% |
WinANIP / S&P 36.72% / 0.20% |
LoseANIP / S&P -76.77% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | ANIP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -22.14% | 20.78% |
| Annualized return | -22.14% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | ANIP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 137.29% | 83.14% |
| Annualized return | 18.87% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | ANIP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 18.53% | 319.30% |
| Annualized return | 1.71% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-24.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |